{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:08:58Z","timestamp":1791648538008,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.leukres.2022.107005","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T19:50:28Z","timestamp":1671825028000},"page":"107005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-1559","authenticated-orcid":false,"given":"Delphine","family":"Lebon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"Dujardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Caulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Joris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Gruson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-3148","authenticated-orcid":false,"given":"Sandrine","family":"Castelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-4253","authenticated-orcid":false,"given":"Catherine","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Lacassagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Marolleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2022.107005_bib1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","article-title":"Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation","volume":"25","author":"Abedin","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2022.107005_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-016-0298-6","article-title":"Ruxolitinib in steroid refractory graft-vs.-host disease: a case report","volume":"9","author":"Maffini","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2022.107005_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","article-title":"Ruxolitinib as salvage therapy for chronic graft-versus-host disease","volume":"25","author":"Modi","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2022.107005_bib4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2017.03.029","article-title":"Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients","volume":"23","author":"Khandelwal","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2022.107005_bib5","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.107005_bib6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.107005_bib7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/imt-2017-0156","article-title":"Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials","volume":"10","author":"Jagasia","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.leukres.2022.107005_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.107005_bib9","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2014-04-570325","article-title":"JAK inhibitors: a home run for GVHD patients","volume":"123","author":"Teshima","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.107005_bib10","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1073\/pnas.1712452115","article-title":"Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation","volume":"115","author":"Betts","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.leukres.2022.107005_bib11","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.107005_bib12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/leu.2015.218","article-title":"Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function","volume":"30","author":"Perner","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.107005_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","article-title":"Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib","volume":"28","author":"Massa","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.107005_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli Yajnanarayana","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2022.107005_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","article-title":"Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study","volume":"55","author":"G tps","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2022.107005_bib16","first-page":"1","article-title":"Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults","author":"Moiseev","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2022.107005_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.leukres.2022.107005_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.leukres.2022.107005_bib19","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/j.bulcan.2017.10.022","article-title":"How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: a report of the SFGM-TC (update)","volume":"104","author":"Brissot","year":"2017","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.leukres.2022.107005_bib20","unstructured":"Kalbfleisch, J.D., Prentice, R.L.: The Statistical Analysis of Failure Time Data. Presented at the (1980)."},{"key":"10.1016\/j.leukres.2022.107005_bib21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/biostatistics\/kxn009","article-title":"Time-dependent covariates in the proportional subdistribution hazards model for competing risks","volume":"9","author":"Beyersmann","year":"2008","journal-title":"Biostatistics"},{"key":"10.1016\/j.leukres.2022.107005_bib22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.leukres.2022.107005_bib23","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1002\/sim.8559","article-title":"Authorseka.l haza","volume":"39","author":"Austin","year":"2020","journal-title":"Stat. Med"},{"key":"10.1016\/j.leukres.2022.107005_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","article-title":"Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients","volume":"92","author":"Polverelli","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.107005_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2509","article-title":"Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients","author":"Polverelli","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2022.107005_bib26","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK inhibition impairs NK cell function in myeloproliferative neoplasms","volume":"75","author":"Schps:\/rg","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2022.107005_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.intimp.2017.11.032","article-title":"Repression of interferon 008-5472.CAN-14-3198eloproliferative neoplasms myelofibrosis patients receiving ruxolitinib","volume":"54","author":"Febvre-James","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.leukres.2022.107005_bib28","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622003812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622003812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:26Z","timestamp":1758935006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622003812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"alternative-id":["S0145212622003812"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.107005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.107005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107005"}}